"Qingke Biotech" received another 400 million yuan in Series B financing to accelerate the construction of "gene factory"

BEIJING, Dec.
5, 2022 /PRNewswire/ -- Beijing Qingke Biotechnology Co.
, Ltd.
(hereinafter referred to as "Qingke Biotechnology"), a strong gene synthesis company in China, recently received another 400 million yuan in financing
.
This round of financing was co-led by Henan Investment Group Huirong Fund and Dachen Caizhi, with the participation of Kailian Capital, Qingsong Capital, Zhongyuan Asset, Jinyu Bogor and other institutions, and Huasheng Capital and Kaicheng Capital acting as financial advisors
.
This round of financing is mainly used for the R&D investment, technology platform upgrade and talent team expansion of Qingke Biogene Factory, as well as the layout of promoting international operation to create an intelligent and automated production platform
that meets global standards.

In May 2022, the national 14th Five-Year Plan sounded the clarion
call to enter the era of "bioeconomy".
The plan proposes to accelerate the improvement of biotechnology innovation capabilities, accelerate the extensive empowerment of biotechnology in health, agriculture, energy, environmental protection and other industries, and promote the diversified development of the bioeconomy, of which gene synthesis, as an important underlying enabling technology of the bioeconomy, will play a key role in promoting and promoting technology
.
According to the National Development and Reform Commission's Innovation Drive Center, the total bioeconomy is expected to reach 22 trillion yuan
by 2025.
Genes as the basis of the genetic material of life, in the era of bioeconomy, genes reshape the world, change human production and lifestyle, achieve cross-border integration of biology, information and materials, and the demand for enabling technology gene synthesis in the entire industry has grown significantly, according to the Oligonucleotide synthesis market 2021 report released by Markets and Markets Research.
The global gene synthesis market will exceed 100 billion RMB
in 2026.

Beijing Tsingke Biotechnology Co.
, Ltd.
is a gene synthesis platform enterprise with an independent whole industry chain, covering three major directions
: synthetic genomics products and services, life science raw materials and equipment, and biomanufacturing CXO.
Qingke Biotech integrates raw materials, synthetic instruments and equipment, synthesis technology and services as one, realizes the self-aggregation of production factors of gene factories, and is in the forefront of the domestic industry in the construction of the whole industry chain of gene synthesis, with significant technical and cost advantages
.
Based on innovative gene intelligent molecule splitting and assembly technology, combined with the AI algorithm of TSINGKE HELIXTECH, Qingke Biotech connects raw materials, equipment and processes to build an intelligent production line, and through accurate genetic detection and quality inspection technology, jointly realizes low-cost, high-efficiency and high-quality synthesis services
。 In terms of service network, Qingke Biotech currently has 8 wholly-owned subsidiaries, 1 holding subsidiary and 17 branches across the country, building a strong network system and proprietary logistics system, covering more than 80% of major cities in China, as well as markets in Europe, America, Southeast Asia and other markets, with the ability to respond quickly to customer needs, and providing products and services
to nearly 200,000 users around the world.

After the A round of financing, Qingke Biotech has achieved a series of major milestones, including the signing of a strategic cooperation agreement on oligonucleotide synthesis of hundreds of millions of yuan, the commissioning of a new plant of Hubei Qingke molecular reagents, the commissioning of the self-developed Oligo automated synthesis production line in Tianjin, and the production of Suzhou Zixi modified probe production base
.
In addition, Qingke Biotech has carried out in-depth cooperation with Academician Zheng Yuguo to deeply participate in synthetic biology manufacturing
with the help of gene synthesis advantages.

Ma Shijin, founder, chairman and general manager of Qingke Biologics, said: "I am very grateful to all professional investment institutions for their recognition and support
to Qingke Biologics.
Since the establishment of the company, we have aimed at the huge development space of the gene synthesis industry, and firmly followed the road
of independent research and development and integrated innovation.
The company's development path is generally from "synthesis technology" to "synthesis platform", and then to the development path of intelligent "gene production factory" independently built by all production factors
.
Over the years, the development of bioeconomy and life sciences has promoted the rapid growth of Kingtech, and its innovative technology, scale advantages and cost advantages continue to feed back the development of
the industry.
Du Jun, vice president of strategy and technology, also said that this round of financing will further promote the company's in-depth technological innovation in high-throughput, high-capacity and high-quality gene synthesis from the strategic level, focusing on cultivating and laying out production capacity and system construction
in biomedical applications in the direction of oligonucleotide drugs, CGT, biomanufacturing and other directions.

Dr.
Ge Dangqiao, Deputy General Manager of Henan Investment Group Huirong Fund, said: Henan Investment Group has actively deployed the biological industry
in recent years.
In 2022, the Henan Emerging Industry Guidance Fund managed by us also established a special sub-fund
for synthetic biology with a target size of 1.
5 billion yuan.
As a platform enterprise in the field of gene synthesis, Qingke Biotech is located in the upstream of the biological industry, providing basic technologies and services for the entire industry, playing the role of "water seller", and is the supporting force
for the future outbreak of synthetic biology and gene therapy industry.
More importantly, Qingke Biotech pays attention to improving its independent innovation capabilities, realizes the layout of the whole industry chain, grasps the opportunities brought by the acceleration of biomedical industry, synthetic biology manufacturing and domestic substitution of core equipment, and has rich imagination for future business expansion and unlimited market space development
.

Dr.
Xu Yuanping, Managing Director of Dachen Caizhi, said: "As an investment institution that has been deeply engaged in the medical and health field for many years, we will pay more attention to the underlying logic
of industry growth.
Looking ahead, in the field of life sciences, whether research, diagnostics, therapeutics or manufacturing, will fully enter the era
of gene-dominated molecules.
As a banner of the gene synthesis industry, Qingke Biotech has advanced underlying independent research and development capabilities (synthetic raw materials, synthetic instruments and equipment, synthesis technology), solid precipitation and leading layout all play an important role
in the company's development.

Zhou Lixin, Managing Director of Kylink Capital, said: "In addition to the leading scale advantage in the gene synthesis industry, Qingke Biotech also has full coverage of gene synthesis technology
.
At the same time, Qingke Biotech has long been based on self-developed synthetic instruments, raw materials and carriers, separation and purification technology and automated production lines
.
The technology and equipment achievements accumulated over the years will eventually help enterprises achieve multi-scenario business coverage and huge
room for expansion.

Dr.
Sui Xiao, Chairman of Qingsong Capital, said: "Qingsong Capital focuses on medical and health industries, and Qingke Biotech has built a perfect gene synthesis platform by virtue of the advantages of the whole gene synthesis industry chain.

Wang Wenli, General Manager of Investment Banking Division of Centaline Asset, said: "Centaline Asset is committed to serving the real economy, and hopes to serve the industrial development
of Henan by investing in a platform enterprise such as Qingke Biotechnology, grafting advanced technology and scientific research teams.

Wang Dong, Partner of Jinyu Bogor, said: "The medical and pharmaceutical health industry is one of the core investment areas of Jinyu Bogor for a long time, and it is a great honor to participate in this round of financing
of Qingke Biotechnology.
In the process of visiting customers in the industry, the quality and service efficiency of Kingtech have been highly praised
by customers.
Among these already well-known customer bases, Qingke can continue to develop new business cooperation, which has great potential, and we are optimistic about this virtuous cycle and continuous reduction of marginal cost business model
.
Under the leadership of the management, Qingke Biotech will definitely make new breakthroughs
.

Dr.
Duan Zhigang, Partner of Huasheng Capital, said: "In today's booming bioindustry, the ability of gene synthesis and sequencing is the "first driving force"
for the development of the industry.
Like the genes it synthesizes, the company is constantly moving
forward with higher throughput, higher capacity and stronger intelligence.
Huasheng Capital is honored to serve as a financial advisor again, and it is even more honored to participate in witnessing the far-sighted layout of Qingke Biotech become a reality
step by step.
In the Series A and this round of financing, we believe that Kingtech will have solid and long-term development
in gene synthesis and related applications.

Dr.
Zou Guowen, founder of Kaicheng Capital, said: "Qingke Biotech is an intelligent gene factory platform integrating raw material production, synthesis equipment and process development, and automated production in China, with advanced design, synthesis, assembly technology and gene synthesis platform system, full coverage of multi-level product layout, strong service network system and experienced and super executive management team
.
We believe that Qingke Biotech will further exert its advantages through the "gene factory", continue to make breakthroughs, and provide the driving force
for the development of biomedicine, biomanufacturing, environmental protection and other fields.

In the future, Qingke Biotech will further increase investment in technology research and development, give full play to the advantages of intelligent, customized and large-scale gene factories, accelerate the application of gene factories in different scenarios, and contribute to life sciences, medical health and other industries
.